Core Insights - Ovid Therapeutics Inc. has reported earnings and revenue that surpassed estimates, indicating strong operational momentum and improving financial health [3][4][6] Company Overview - Ovid Therapeutics is a biopharmaceutical company focused on developing treatments for rare neurological disorders and brain conditions with significant unmet needs [2] - The company operates within the Zacks Medical - Biomedical and Genetics industry, competing in the development of innovative therapies [2] Financial Performance - For Q4 2025, Ovid reported earnings per share of $0.06, exceeding the Zacks Consensus Estimate of a $0.10 loss, representing a substantial earnings surprise of approximately +158-161% [3][6] - The company's revenue for Q4 2025 was $718,000, significantly higher than pre-release estimates ranging from ~$13,000 to $80,000, showcasing strong growth [4][6] Financial Position - Ovid's financial position is supported by cash, cash equivalents, and marketable securities, bolstered by a private placement in October 2025, which raised approximately $81 million upfront [5][6] - This funding is expected to support key studies for drug candidates OV329 and OV4071 and sustain operations into the second half of 2028 [5] - The price-to-sales ratio is around 22x, indicating investor optimism regarding Ovid's future growth prospects in its differentiated neurological pipeline [5]

Core Insights - Ovid Therapeutics reported positive safety and tolerability results for OV329 in drug-resistant epilepsies, with no treatment-related adverse events in the 7 mg cohort [1] - The company plans to expand OV329's development to include tuberous sclerosis complex seizures and infantile spasms, with a proof-of-concept study expected to start in Q4 2026 [1] - Ovid received clearance for Phase 1 clinical trials of OV4071, targeting psychosis associated with Parkinson's disease and Lewy body dementia [2] - A private investment of $60 million was announced, with shares priced at $2.01, expected to fund operations into late 2028 [3] - The company reported $90.4 million in cash and equivalents as of December 31, 2025, which will support key studies for OV329 and OV4071 [3] - The exercise of outstanding warrants may extend the cash runway into 2029 [4] Technical Analysis - Ovid's stock is trading 36.2% above its 20-day SMA of $1.77 and 51.2% above its 100-day SMA of $1.59, indicating a strong upward trend [5] - The RSI is at 63.49, and the MACD shows bullish momentum at 0.1210, suggesting mixed momentum [5] - Ovid Therapeutics shares increased by 14.42% to $2.29 at the time of publication, with key resistance at $2.50 and support at $2.00 [6]

Financial Data and Key Metrics Changes - As of December 31, 2025, Ovid Therapeutics reported $90.4 million in cash equivalents and marketable securities [42] - The company announced a PIPE financing with gross proceeds totaling $60 million, which is expected to extend the cash runway into the second half of 2028 [42] - If the Series A warrants are fully exercised, the pro forma cash runway could extend well into 2029 [42] Business Line Data and Key Metrics Changes - The company received regulatory clearance for OV4071, the first-ever oral KCC2 direct activator, a quarter earlier than expected [5] - OV329, a next-generation GABA aminotransferase inhibitor, has shown no serious adverse events at the 7 mg dose, indicating a strong safety and tolerability profile [5][13] - The company is launching additional studies for OV329 in infantile spasms and seizures associated with tuberous sclerosis complex, supported by new capital [7][8] Market Data and Key Metrics Changes - The market opportunity for OV329 is significant, especially in treating conditions like infantile spasms and tuberous sclerosis complex, where current treatment options are limited [24][27] - The peak sales of vigabatrin (Sabril) reached over $320 million, indicating a substantial market despite safety concerns that limited its use [79] Company Strategy and Development Direction - Ovid Therapeutics aims to develop safer, more effective treatments for neural hyperexcitability, focusing on small molecule programs [9] - The company plans to initiate a phase II randomized placebo-controlled trial for OV329 in focal onset seizures in Q2 2026, with a focus on traditional efficacy endpoints [59] - The strategy includes developing differentiated formulations for adult and pediatric populations, allowing for differential pricing based on specific needs [70] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of OV329 to be used earlier and longer in treatment regimens, which could change disease trajectories for patients [78] - The company is optimistic about the upcoming trials and the potential for OV4071 to address a broad range of psychosis applications [34][36] - Management emphasized the importance of robust safety data to support regulatory submissions and avoid the limitations faced by previous treatments [50] Other Important Information - The company does not plan to host regular quarterly earnings calls moving forward, indicating a shift in communication strategy [4] - Ovid Therapeutics is preparing for a KCC2 day event to provide further insights into their KCC2 program and future candidates [33] Q&A Session Summary Question: Can you provide more detail on OV329 and the visual monitoring? - Management confirmed that optic and retinal monitoring will continue through phase II and pivotal studies to ensure robust safety data [50] Question: What are the key endpoints for the planned phase II design for OV329? - The phase II study will target adults with treatment-resistant focal onset seizures, focusing on traditional efficacy endpoints such as percent reduction in seizures [59] Question: What type of patients will be enrolled in the open-label photosensitive epilepsy study? - The study will enroll adults with diagnosed epilepsy and documented photosensitivity, using a specialized site in the Netherlands [67] Question: How does the company view the long-term clinical development for OV329? - Management believes OV329 has broad therapeutic utility and will use evidence from ongoing studies to inform future development directions [91]

Financial Data and Key Metrics Changes - As of December 31, 2025, Ovid Therapeutics reported $90.4 million in cash equivalents and marketable securities [42] - The company announced a PIPE financing with gross proceeds totaling $60 million, which is expected to extend the cash runway into the second half of 2028 [42] - If the Series A warrants are fully exercised, the pro forma cash runway could extend well into 2029 [42] Business Line Data and Key Metrics Changes - The company received regulatory clearance for OV4071, the first-ever oral KCC2 direct activator, a quarter earlier than expected [5] - OV329, a next-generation GABA aminotransferase inhibitor, has shown no serious adverse events at the 7-milligram dose, indicating a strong safety and tolerability profile [5][13] - The company is launching additional studies for OV329 in infantile spasms and seizures associated with tuberous sclerosis complex, supported by new capital [7][8] Market Data and Key Metrics Changes - The market opportunity for OV329 is significant, especially in treating conditions like infantile spasms and tuberous sclerosis complex, where current treatment options are limited [24][27] - The peak sales of Sabril (Vigabatrin) reached over $320 million, indicating a substantial market potential for a safer alternative like OV329 [79] Company Strategy and Development Direction - Ovid Therapeutics aims to develop gentler, better medicines for the brain, focusing on controlling neural hyperexcitability through small molecule programs [9] - The company plans to initiate a phase 1 study for OV4071 and a ketamine challenge study to demonstrate proof of mechanism [33][40] - The strategy includes developing differentiated formulations for adult and pediatric populations, allowing for differential pricing based on the specific needs of each community [70] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of OV329 to be used earlier and longer in treatment, which could change the trajectory of diseases for children with severe conditions [78] - The company is optimistic about the upcoming milestones and catalysts, indicating a busy couple of years ahead [37] Other Important Information - Ovid Therapeutics does not plan to host regular quarterly earnings calls moving forward, indicating a shift in communication strategy [4] - The company is preparing for a KCC2 day to provide more insights into the KCC2 portfolio and its therapeutic potential [36] Q&A Session Summary Question: Can you provide more detail on OV329 and the visual monitoring? - Management confirmed that optic and retinal monitoring will continue through phase 2 and pivotal studies to ensure robust safety data [50] Question: What are the key endpoints for the planned phase two design for OV329? - The phase 2 study will target adults with treatment-resistant focal onset seizures, focusing on traditional endpoints like percent reduction in seizures and CGI endpoints [59] Question: What type of patients will be enrolled in the open-label photosensitive epilepsy study? - The study will enroll adults with diagnosed epilepsy and documented photosensitivity, using intermittent photic stimulation for screening [67] Question: How does the company plan to address long-term clinical development for OV329? - Management indicated that OV329 has broad therapeutic utility and that evidence will inform potential expansions into other indications [91]

Financial Data and Key Metrics Changes - As of December 31, 2025, Ovid Therapeutics reported $90.4 million in cash equivalents and marketable securities [40] - The company announced PIPE financing with gross proceeds totaling $60 million, which is expected to extend the cash runway into the second half of 2028 [40] - Pro forma cash runway is anticipated to extend well into 2029, assuming full exercise of Series A warrants triggered by regulatory clearance [40] Business Line Data and Key Metrics Changes - The company received regulatory clearance for OV4071, the first-ever oral KCC2 direct activator, a quarter earlier than expected [4] - OV329, a next-generation GABA aminotransferase inhibitor, has shown no serious adverse events at the 7-milligram dose, indicating a strong safety and tolerability profile [5][11] - The company is launching additional studies for OV329 in infantile spasms and tuberous sclerosis complex, expanding its clinical pipeline [5][19] Market Data and Key Metrics Changes - The market opportunity for OV329 is significant, especially in treating conditions like infantile spasms and tuberous sclerosis complex, where current treatment options are limited [20][25] - The peak sales of Sabril (Vigabatrin) reached over $320 million, indicating a substantial market despite safety concerns that limited its use [76] Company Strategy and Development Direction - Ovid Therapeutics aims to develop safer and more effective treatments for neural hyperexcitability, focusing on small molecule programs [6][7] - The company plans to initiate a phase 2 randomized placebo-controlled trial for OV329 in focal onset seizures and is also exploring pediatric formulations for underserved populations [17][68] - The strategic focus includes expanding the use of OV329 beyond focal onset seizures to potentially include status epilepticus in the future [92] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the safety and efficacy of OV329, emphasizing the importance of robust safety data to support regulatory submissions [48] - The company is optimistic about the potential of OV4071 in treating various psychosis-related conditions, with plans for further data releases in the coming months [32][34] - Management highlighted the importance of addressing unmet needs in epilepsy treatment, particularly for pediatric patients [19][21] Other Important Information - The company does not plan to host regular quarterly earnings calls moving forward, indicating a shift in communication strategy [3] - The clearance of OV4071 triggers a 30-day period for Series A warrants, which could bring in additional capital exceeding $53 million [6] Q&A Session Summary Question: Can you elaborate on the visual monitoring for OV329? - Management confirmed that optic and retinal monitoring will continue through phase 2 and pivotal studies to ensure robust safety data [47] Question: What are the key endpoints for the phase 2 design of OV329? - The phase 2 study will target adults with treatment-resistant focal onset seizures, focusing on traditional endpoints like percent reduction in seizures and CGI endpoints [58] Question: What is the rationale for the ketamine challenge study for OV4071? - The ketamine challenge aims to demonstrate that OV4071 is effectively entering the brain and exhibiting GABAergic activity, with plans to correlate this with clinical symptom improvement [60] Question: What patient population will be enrolled in the open-label photosensitive epilepsy study? - The study will enroll adults with diagnosed epilepsy and documented photosensitivity, using specialized sites for the research [65] Question: How does the company plan to address differential pricing for different populations? - The company plans to develop differentiated formulations for adult and pediatric populations, allowing for appropriate and responsible differential pricing [68]

Business and pipeline update March 18, 2026 © Copyright 2026 Ovid Therapeutics Forward-looking statements This presentation includes certain disclosures by Ovid that contain "forward-looking statements" including, without limitation statements regarding: the reproducibility and durability of any favorable results initially seen to date in clinical trials; the potential therapeutic opportunity of OV329, OV4071 and other compounds from Ovid's library of direct activators of KCC2; the expected timing of initia ...

Core Insights - Ovid Therapeutics Inc. reported progress in its pipeline and business updates, highlighting favorable results for OV329, a GABA-AT inhibitor, and plans for additional development programs [1][3][4] Pipeline and Business Updates - OV329 demonstrated a favorable safety and tolerability profile in a 7 mg dose cohort, leading to plans for patient studies [4][5] - The company is expanding OV329's development to include tuberous sclerosis complex (TSC) seizures and infantile spasms (IS), supported by a $60 million private placement [1][6][10] - A Phase 1 trial for OV4071, a first-in-class oral KCC2 direct activator, has been approved and is set to begin [2][14] - Ovid plans to host a KCC2-focused R&D Day on April 14, 2026, to discuss its KCC2 portfolio [6][14] Financial Results - As of December 31, 2025, Ovid reported $90.4 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into late 2028 [6][23] - The company reported a net income of $9.7 million for Q4 2025, compared to a net loss of $9.3 million in Q4 2024, primarily due to a gain from a long-term equity investment [27][30] - Total revenue for 2025 was $7.3 million, an increase from $0.6 million in 2024, driven by royalties and a one-time payment [23][30] Clinical Development Plans - Ovid plans to initiate a Phase 2 trial for OV329 in focal onset seizures and an open-label proof-of-concept study in Q2 2026 [9][20] - The company is also advancing a pediatric-specific formulation of OV329 for use in infants and children [12][11] - A ketamine challenge study for OV4071 is planned for mid-2026 to explore its pharmacodynamic effects [16][20] Business Strategy - The approval of OV4071 triggers a 30-day period for the exercise of Series A Warrants, potentially raising an additional $53.9 million [17][18] - Proceeds from the recent private placement will support the expansion of OV329 into additional indications [19][18]

Core Viewpoint - Ovid Therapeutics Inc. has announced a private investment in public equity (PIPE) financing expected to generate gross proceeds of $60 million to support the development of its brain disorder treatments [1][10]. Group 1: Financing Details - The PIPE financing is led by Point72, with participation from several existing investors including Adage Capital Management and RA Capital Management [2][10]. - The company will sell a total of 19,154,321 shares of common stock at a price of $2.01 per share, along with pre-funded warrants for up to 10,701,710 shares at a price of $2.009 each [3]. - The pre-funded warrants will have an exercise price of $0.001 per share and will be immediately exercisable [3]. Group 2: Use of Proceeds - The net proceeds from the PIPE financing will be used to expand the development of OV329 into additional indications, including tuberous sclerosis complex and infantile spasms, as well as for general research and development expenses [4]. Group 3: Company Overview - Ovid Therapeutics is focused on developing small molecule medicines for brain disorders with significant unmet needs, advancing a pipeline that includes OV329, a next-generation GABA-aminotransferase inhibitor [8].

Summary of Ovid Therapeutics Conference Call Company Overview - **Company**: Ovid Therapeutics (NasdaqGS:OVID) - **CEO**: Meg Alexander, who has been in the role for approximately two and a half months [1][5][11] Key Product: OV329 - **Mechanism of Action**: OV329 is designed to elevate endogenous levels of GABA, potentially serving as a significant anticonvulsant for epilepsy [15][19] - **Differentiation**: It represents a novel mechanism of action in a field that has seen only two new mechanisms in the last 20 years, addressing a critical need for new treatment options for patients resistant to current therapies [15][17] - **Tolerability**: Early data suggests OV329 may be better tolerated than existing seizure medications, with no drug-drug interactions and no need for titration [17][18] - **Development Status**: The company plans to initiate a randomized placebo-controlled Phase 2 study with a 7-milligram dose in Q2 2026, with results expected by mid-2026 [38][41][43] Clinical Data and Efficacy - **Preclinical and Clinical Data**: OV329 has shown promising preclinical results, including cortical inhibition in healthy volunteers, and elevated GABA levels consistent with its mechanism [34][35][37] - **Seizure Reduction Goals**: The company aims for a seizure reduction efficacy of 30-50% in focal onset seizures, emphasizing the importance of tolerability alongside efficacy [61][63] Competitive Landscape - **Market Positioning**: Ovid Therapeutics has strategically chosen to focus on differentiated mechanisms rather than competing in crowded areas with multiple similar drugs [64][67] - **Future Outlook**: The company believes there is potential for OV329 to become a significant player not only in focal onset seizures but also in pediatric epilepsies [67] Additional Product: KCC2 (OV4071) - **Mechanism**: KCC2 is a potassium chloride cotransporter that plays a crucial role in GABAergic signaling and is neuron-specific, reducing the risk of off-target effects [81][84] - **Therapeutic Potential**: The company sees KCC2 as a promising target with potential applications across various conditions, including psychoses and pain [85][135] - **Initial Indications**: The focus for OV4071 includes Parkinson's disease psychoses and schizophrenia, with plans to explore broader applications based on emerging data [135][136] Development Strategy - **Indication Selection**: Ovid Therapeutics is prioritizing indications based on mechanistic rationale and existing data, aiming to mitigate risks in clinical trials [138] - **Future Pipeline**: The company has multiple development candidates related to KCC2 that have not yet been publicly discussed, indicating a robust pipeline for future growth [149] Conclusion - Ovid Therapeutics is positioned to make significant advancements in the treatment of epilepsy and related disorders through its innovative products OV329 and OV4071, with a strong focus on tolerability and efficacy in a competitive landscape. The company is actively preparing for upcoming clinical trials and regulatory discussions to further its development goals.

Summary of Ovid Therapeutics FY Conference Call Company Overview - **Company**: Ovid Therapeutics (NasdaqGS:OVID) - **Focus**: Central nervous system (CNS) disorders, specifically small molecule medicines targeting biological mechanisms in the brain related to neural excitation and inhibition [2][3] Key Points and Arguments Pipeline and Strategy - Ovid has curated a pipeline focused on differentiated mechanisms of action in neurology and neuropsychiatry, aiming to develop category-leading medicines [3][4] - The company anticipates significant data releases and progress across its assets in the next 6-18 months [4] Epilepsy Program (OV329) - **Mechanism**: OV329 is a GABA aminotransferase inhibitor, which increases GABA levels, the main inhibitory neurotransmitter in the brain [5][6] - **Clinical Data**: Recent data indicates OV329 shows inhibition in the brain comparable to therapeutic doses of existing seizure medications, with better tolerability [5][6][11] - **Next Steps**: An open-label study and a Phase 2 trial are planned for this year, with results expected by mid-next year [6][15] KCC2 Portfolio - **Target**: KCC2 (potassium-chloride cotransporter 2) has broad therapeutic applications but has been challenging to drug [6][18] - **Progress**: Ovid has shown the ability to safely drug this target and is preparing to submit for regulatory clearance and initiate human studies [7][8][19] Competitive Landscape - Ovid's OV329 is differentiated from other epilepsy drugs, particularly sodium channel drugs, as it does not have the same tolerability issues and allows for better polypharmacy options [26][28] - The company believes OV329 could be a significant advancement in treating treatment-resistant epilepsy, where approximately 40% of patients require multiple medications [27][28] Safety and Efficacy - OV329 is expected to have a favorable safety profile, avoiding the idiosyncratic safety issues seen with first-generation drugs like vigabatrin [10][38] - The company aims for a competitive seizure reduction efficacy of 30-50% from baseline in the upcoming trials [79][80] Future Directions - Ovid is exploring additional indications for its KCC2 portfolio, including psychosis associated with Parkinson's disease and Alzheimer's agitation [22][87] - The company is utilizing advanced biomarkers and electrophysiological techniques to guide its development strategy [93] Other Important Content - The conference highlighted the importance of developing CNS drugs that are effective without significant side effects, addressing a critical need in the market [28][59] - Ovid's approach to drug development emphasizes safety, tolerability, and the ability to work alongside existing medications, which is crucial for patient care [70][82]